Chronic Hepatitis C
Conditions
Interventions
All patients are treated with PEG-IFN alfa-2b 1.0-1.5 microgram/kg/week + Ribavirin 400-1000/day. Treatment duration is 48-72 weeks for HCV genotype1 with high viral load and up to 24 weeks for HCV g
Sponsors
Tokushima Municipal Hospital
Musashino Red Cross Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Platelet count <80,000/mm3 before PSE or splenectomy 2)Platelet count 80,000/mm3 or more before initiation of PEG-IFN alfa-2b + Ribavirin treatment 3)High serum HCV levels of 5 log IU/ml or more(TaqMan) or previous IFN treatment failure
Exclusion criteria
Exclusion criteria: 1)History of hypersensitivity to PEG-IFN alpha-2b or other interferons 2)History of hypersensitivity to biological products such as vaccine 3)Patients receiving shosaiko-to 4)Autoimmune hepatitis 5)Pregnant or lactating women and women who may be pregnant 6)History of hypersensitivity to ribavirin or other nucleoside analogs 7)Inadequately controlled cardiac disease 8)Hemoglobinopathy 9)Chronic renal failure or renal function disorder with creatinine clearance of 50 ml/min or less 10)With or with a history of severe psychosis such as severe depression, suicidal ideation or attempt, etc. 11)Serious hepatic function disorder 12)Judged by investigator not to be appropriate for inclusion in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sustained virological response(SVR) | — |
Countries
Japan
Contacts
Public ContactAkemi Tsutsui
Tokushima Municipal Hospital Department of Internal Medicine
Outcome results
None listed